1. KimW.Review of antibiotics in clinical development pipeline. The Pew Charitable Trusts.2019. Available from:https://www.fda.gov/media/133086/download
2. Nabriva Therapeutics. Nabriva Therapeutics receives U.S. FDA approval of Xenleta™ (lefamulin) to treat community‐acquired bacterial pneumonia (CABP).2019. Available from:https://investors.nabriva.com/news‐releases/news‐release‐details/nabriva‐therapeutics‐receives‐us‐fda‐approval‐xenleta
3. Nabriva Therapeutics. XENLETA® (lefamulin) receives Health Canada approval for treatment of community acquired pneumonia.2020. Available from:https://investors.nabriva.com/news‐releases/news‐release‐details/xenletar‐lefamulin‐receives‐health‐canada‐approval‐treatment
4. Nabriva Therapeutics. NABRIVA receives European approval for XENLETA® (lefamulin) for treatment of community‐acquired pneumonia (CAP).2020. Available from:https://investors.nabriva.com/news‐releases/news‐release‐details/nabriva‐receives‐european‐approval‐xenletar‐lefamulin‐treatment
5. DadonaiteB RoserM.Pneumonia. Our World in Data;2018. Available from:https://ourworldindata.org/pneumonia